Analysts' Actions: COF, EA, NYX, MAKO

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

AAR Corp. ( AIR) was downgraded to Hold at TheStreet Ratings.

Aecom Technology ( ACM) was downgraded at Bank of America/Merrill Lynch to Underperform. $20 price target. Company lacks near-term catalysts and is a potential value trap, BofA/Merrill said.

Capital One ( COF) was upgraded at Argus from Sell to Hold. Valuation call.

Cognizant ( CTSH) was upgraded from Neutral to Outperform at Robert Baird. Valuation call, based on a $76 price target, Baird said.

Dresser-Rand ( DRC) was upgraded at Morgan Stanley from Equal-Weight to Overweight. $65 price target. Lower natural gas prices are boosting demand for downstream activity, Morgan Stanley said.

Electronic Arts ( EA) was upgraded at Needham from Hold to Buy. $22 price target. Strong sales growth can expand margins, Needham said.

Goldman Sachs ( GS) was downgraded to Hold at TheStreet Ratings.

HSN ( HSNI) was upgraded at Citigroup to Buy from Neutral. $42.50 price target. Compelling valuation and accelerating buyback, Citi said.

Louisiana-Pacific ( LPX) was upgraded at Deutsche Bank from Hold to Buy. $12 price target. Housing demand is beginning to recover, Deutsche said.

Mako Surgical ( MAKO) was downgraded at William Blair to Market Perform. Estimates were also cut, given the company's new guidance, William Blair said.

Millennial Media ( MM) was initiated with an Equal-weight rating at Morgan Stanley. Valuation call, Morgan Stanley said.

NYSE Euronext ( NYX) was upgraded at Stifel Nicolaus from Sell to Hold. Valuation call, Stifel Nicolaus said.

Rexnord ( RXN) was initiated with a Neutral rating at Goldman Sachs. Valuation call, based on a $24 price target, Goldman said.

Synchronoss ( SNCR) was downgraded at Wells Fargo to Market Perform. Company cut its guidance because of AT&T ( T), Wells Fargo said.

Vertex Pharmaceuticals ( VRTX) was upgraded at Morgan Stanley from Underweight to Equal-Weight. $51 price target. Interim cystic fibrosis data were better than expected, Morgan Stanley said.

Vertex Pharmaceuticals was upgraded at Brean Murray. Cystic Fibrosis treatment is performing better than expected in trials. Brean Murray said.

Exco Resources ( XCO) was upgraded at Keybanc from Hold to Buy. $10 price target. Stock has underperformed, but the company is getting aggressive with its cost controls, Keybanc said.

Cimarex Energy ( XEC) was upgraded at Canaccord Genuity from Hold to Buy. $84 price target. Stock is attractive, following a 20% decline, Canaccord said.

Cognizant Technology Solutions ( CTSH) numbers were lowered at Oppenheimer. Shares are now seen reaching $72. Estimates were also lowered on guidance moderation, Oppenheimer said. Outperform rating.

Dish Network ( DISH) estimates were cut at Credit Suisse through 2013. Company is facing higher programming costs, Credit Suisse said. Outperform rating and $34 price target.

Dish Network estimates were raised at UBS through 2013. Renewed focus on product and brand are starting to gain traction, UBS said. Neutral rating and $32 price target.

Dendreon ( DNDN) estimates, target were reduced at Credit Suisse. Shares are now seen reaching $12. Estimates were also cut, given the company's new guidance, Credit Suisse said. Neutral rating.

Electronic Arts ( EA) numbers were lowered at Citigroup. Shares are now seen reaching $19. Estimates were also lowered on negative fundamental trends, Citi said. Buy rating.

Family Dollar ( FDO) price target was boosted at JP Morgan to $75. Company has a solid strategy to improve profitability, JP Morgan said. Overweight rating.

Fresh Del Monte ( FDP) numbers were raised at Jefferies. Shares are now seen reaching $26. Estimates were also raised on better-than-expected profitability, Jefferies said. Hold rating.

Mid-America Apartments ( MAA) price target was raised at Jefferies to $77. Still an attractive GARP play, Jefferies said. Buy rating.

Nordic American Tanker ( NAT) numbers were lowered at Jefferies. Shares are now seen reaching $11. Estimates were also lowered on poor first quarter, Jefferies said. Hold rating.

Salix Pharmaceuticals ( SLXP) numbers were raised at Jefferies. Shares are now seen reaching $63. Estimates were also raised on beat and raise, Jefferies said. Buy rating.

Wynn Resorts ( WYNN) price target was lowered at JP Morgan. Shares are now seen reaching $160. Company is facing higher costs in Macau and seeing lower occupancy in Las Vegas, JP Morgan said. Overweight rating.

Wynn Resorts numbers were raised at UBS. Shares are now seen reaching $165. Estimates also increased on record Macau VIP volume, UBS said. Buy rating.

Wynn Resorts estimates raised at Citigroup through 2013. Will continue to lose market share to Cotai before its own property opens, Citigroup said. Neutral rating and $150 price target.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.

More from Stocks

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

What Will GM Do With Cruise -- and Is Its Stock Worth $55?

What Will GM Do With Cruise -- and Is Its Stock Worth $55?

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

This Should Be Your Retirement Savings Plan When the Stock Market Crashes

This Should Be Your Retirement Savings Plan When the Stock Market Crashes